SARS-COV-2 MPRO INHIBITORS AND USES THEREOF

This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical comp...

Full description

Saved in:
Bibliographic Details
Main Authors PICKWORTH, Mark, DE GRAAF, Chris, HIGUERUELO, Alicia Perez, CONGREVE, Miles Stuart, CHRISTOPHER, John Andrew, MASON, Jonathan Stephen
Format Patent
LanguageEnglish
French
Published 11.04.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS- CoV-2 and related viruses. La présente demande concerne de nouveaux composés et leur utilisation en tant qu'inhibiteurs de la protéase principale du SARS-CoV-2 (Mpro). Les composés décrits ici peuvent être utiles dans le traitement du SARS-CoV-2 et de virus apparentés, ainsi que des troubles associés au SARS-CoV-2 : Mpro. La demande concerne également des compositions pharmaceutiques comprenant ces composés et la fabrication et l'utilisation de ces composés et compositions dans le traitement du SARS-CoV-2 et de virus apparentés, ainsi que des troubles associés au SARS-CoV-2 : Mpro. Les composés et les compositions peuvent être utiles dans la prévention de la mort ou des complications survenant en raison d'états sous-jacents chroniques ou de comorbidités chez des patients infectés par le SARS-CoV-2 et des virus apparentés.
Bibliography:Application Number: WO2023EP77644